1. Home
  2. Labeler Index
  3. Contract Pharmacy Services-pa
  4. 67046-122
  5. Product Images: Divalproex Sodium

Product Images Divalproex Sodium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Divalproex Sodium NDC 67046-122 by Contract Pharmacy Services-pa, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Divalproex Structural Formula - a24e8e53 07b3 49be 87e4 124f7d3aeac1 01

Divalproex Structural Formula - a24e8e53 07b3 49be 87e4 124f7d3aeac1 01

proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo - a24e8e53 07b3 49be 87e4 124f7d3aeac1 02

proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo - a24e8e53 07b3 49be 87e4 124f7d3aeac1 02

This text describes a chart or graph showing the percentage reduction in CPS (Central Nervous System) rate for patients using Divalproex Sodium Delayed-Release compared to a placebo. The chart shows that 50% of patients experienced an improvement in CPS rate, while some had no change and others experienced worsening.*

proportion of patients achieving any particular level of reduction was consistently higher for high dose valproate than for low dose valproate - a24e8e53 07b3 49be 87e4 124f7d3aeac1 03

proportion of patients achieving any particular level of reduction was consistently higher for high dose valproate than for low dose valproate - a24e8e53 07b3 49be 87e4 124f7d3aeac1 03

The text represents a table showing the percentage reduction in CPS rate among different groups of patients using high and low dose divalroex sodium delayed release and Lom dose Diaproex Sodium Delayed Release. The table also measures the percentage of patients who experienced improvement, no change, or worsening in CPS rate.*

Figure 3 Mean Reduction in 4-Week Migraine Headache Rates - a24e8e53 07b3 49be 87e4 124f7d3aeac1 04

Figure 3 Mean Reduction in 4-Week Migraine Headache Rates - a24e8e53 07b3 49be 87e4 124f7d3aeac1 04

Blister of 30 Tablets - a24e8e53 07b3 49be 87e4 124f7d3aeac1 05

Blister of 30 Tablets - a24e8e53 07b3 49be 87e4 124f7d3aeac1 05

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.